Xience V making strides
This article was originally published in The Gray Sheet
Executive Summary
Guidant's everolimus-eluting stent has received a CE mark and will launch in the European Union by June , the company announced Jan. 30. Built on the firm's Multi-Link Vision stenting platform, the Xience V system is being evaluated in the SPIRIT III trial in the U.S. and Japan, with more than 70% of U.S. enrollment complete, the company says...